



INFORMATION DISCLOSURE STATEMENT BY APPLICANT 		Attorney Docket Number	6613-66750-01		
		Application Number	10/659,178		
		Filing Date	September 9, 2003		
		First Named Inventor	David Jonathan Madge		
		Art Unit	1621		
		Examiner Name	To be assigned		
U.S. PATENT DOCUMENTS					
Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee	
YV		5,639,739	17 June 1997	Dominguez et al.	
FOREIGN PATENT DOCUMENTS					
Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
OTHER DOCUMENTS					
YV		Berge et al., "Pharmaceutical Salts," <i>Journal of Pharmaceutical Sciences</i> 66(1):1-19, 1977			

EXAMINER SIGNATURE:	/Yevgeny Valenrod/	DATE CONSIDERED:	01/26/2007
------------------------	--------------------	---------------------	------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.



Attorney Docket Number	6613-66750-01
Application Number	10/659,178
Filing Date	September 9, 2003
First Named Inventor	David Jonathan Madge
Art Unit	1621
Examiner Name	To be assigned

U.S. PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
YV		5,169,841	08 Dec 1992	Kleeman et al.
YV		6,114,308	05 Sept 2000	Claeson et al.
YV		6,297,217	02 Oct 2001	Adams et al.
YV		6,417,174	09 July 2002	Shoichet et al.

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
YV		Europe	EP 0 235 692	19 Feb 1987	Behringwerke Aktiengesellschaft
YV		Europe	EP 0 599 633	24 Nov 1993	Thrombosis Research Institute
YV		WIPO/PCT	WO 89/09612	19 Oct 1989	Corvas, Inc.
YV		WIPO/PCT	WO 94/21668	29 Sept 1994	The DuPont Merck Pharmaceutical Company
YV		WIPO/PCT	WO 98/00443	08 Jan 1998	Thrombosis Research Institute

EXAMINER SIGNATURE: /Yevgeny Valenrod/	DATE CONSIDERED: 01/26/2007
---	--------------------------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.


**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Attorney Docket Number	6613-66750-01
Application Number	10/659,178
Filing Date	September 9, 2003
First Named Inventor	David Jonathan Madge
Art Unit	1621
Examiner Name	To be assigned

Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS
YV		Bastin et al., "Salt Selection and Optimisation Procedures for Pharmaceutical New Chemical Entities," <i>Organic Process Research & Development</i> 4:427-235, 2000
		Brikh et al., "Boronated thiophenols: a preparation of 4-mercaptophenylboronic acid and derivatives," <i>Journal of Organometallic Chemistry</i> 581:82-86, 1999
		Davies et al., "Peroxides of Elements other than Carbon. Part XII. The Autoxidation of Optically Active 1-Phenylethylboronic Acid," <i>J Chem Soc</i> pp. 17-22, 1967
		Elgendi et al., "Design of a novel class of bifunctional thrombin inhibitors, synthesised by the first application of peptide boronates of solid phase chemistry," <i>Tetrahedron Letters</i> 38(18):3305-3308, 1997
		Hsiao et al., "A Facile Synthesis of <i>tert</i> -Butyl 2-[Benzoyloxycarbonyl]amino]-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propionate: An Orthogonally Protected Boronic Acid Analog of Aspartic Acid," <i>Synthesis</i> 7:1043-1046, 1998
		Kettner et al., "Inhibition of the Serine Proteases Leukocyte Elastase, Pancreatic Elastase, Cathepsin G, and Chymotrypsin by Peptide Boronic Acids," <i>The Journal of Biological Chemistry</i> 259(24):15106-15114, 1984
		Kettner et al., "The Selective Inhibition of Thrombin of Peptides of Boroarginine," <i>The Journal of Biological Chemistry</i> 265(30):18289-18297, 1990
		Lappert, "Organic Compounds of Boron," <i>Chem. Review</i> 56:959-1064, 1956
		Martichonok et al., "Cysteine Proteases such as Papain are not Inhibited by Substrate Analogue Peptidyl Boronic Acids," <i>Bioorganic and Medicinal Chemistry</i> 5(4):679-684, 1997
		Skordalakes et al., "Crystallographic Structures of Human α -Thrombin Complexed to Peptide Boronic Acids Lacking a Positive Charge of P1. Evidence of Novel Interactions," <i>J. Am. Chem. Soc.</i> 119:9935-9936, 1997
		Snyder et al., "Organoboron Compounds, and the Study of Reaction Mechanisms. Primary Aliphatic Boronic Acids," <i>Am Chem Soc</i> 60:105-111, 1938
		Snyder et al., "Aryl Boronic Acids. II. Aryl Boronic Anhydrides and their Amine Complexes," <i>Am Chem Soc</i> 80:3611-3615, 1958
▼		Wityak et al., "Synthesis of Thrombin Inhibitor DuP 714," <i>J. Org. Chem.</i> 60:3717-3722, 1995

EXAMINER SIGNATURE:	/Yevgeny Valenrod/	DATE CONSIDERED:	01/26/2007
---------------------	--------------------	------------------	------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.



WR:jam 10/18/04 6613-66750-01 319322
IDS - 10/20/2004

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Attorney Docket Number	6613-66750-01
Application Number	10/659,178
Filing Date	September 9, 2003
First Named Inventor	David Jonathan Madge
Art Unit	1621
Examiner Name	To be assigned

U.S. PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
YV		US-2004-0138175-A1	15 July 2004	Madge et al.
YV		US-2004-0147453-A1	29 July 2004	Deadman et al.

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee

OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Davies, <i>The Pharmaceutical Journal</i> 266:322-323, 2001

EXAMINER SIGNATURE:	/Yevgeny Valenrod/	DATE CONSIDERED:	01/26/2007
---------------------	--------------------	------------------	------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEP 17 2004


**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Attorney Docket Number	6613-66750-01
Application Number	10/659,178
Filing Date	September 9, 2003
First Named Inventor	David Jonathan Madge
Art Unit	1621
Examiner Name	To be assigned

U.S. PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee

OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Other Documents
YV		Davies, <i>The Pharmaceutical Journal</i> 266:322-323, 2001

EXAMINER SIGNATURE:	/Yevgeny Valenrod/	DATE CONSIDERED:	01/26/2007
------------------------	--------------------	---------------------	------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

EXAMINER SIGNATURE:	/Yevgeny Valenrod/	DATE CONSIDERED:	01/26/2007
------------------------	--------------------	---------------------	------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.


**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Attorney Docket Number	6613-66750
Application Number	10/659,178
Filing Date	September 9, 2003
First Named Inventor	David Jonathan Madge
Art Unit	1621
Examiner Name	To be assigned

U.S. PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
YV		WIPO/PCT	WO 96/12499	02 May 1996	The DuPont Merck Pharmaceutical Company

OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Other Documents

EXAMINER
SIGNATURE:

/Yevgeny Valenrod/

DATE
CONSIDERED:

01/26/2007

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

FEB 24 2004

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Attorney Docket Number	6613-66750
Application Number	10/659,178
Filing Date	September 9, 2003
First Named Inventor	David Jonathan Madge
Art Unit	1621
Examiner Name	To be assigned


U.S. PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Date	Name
YV		4,499,082	12 Feb 1985	Shenvi et al.
		4,701,545	20 Oct 1987	Matteson et al.
		4,935,493	19 Jun 1990	Bachovchin et al.
		4,963,655	16 Oct 1990	Kinder et al.
		5,187,157	16 Feb 1993	Kettner et al.
		5,444,049	22 Aug 1995	de Nanteuil et al.
		5,462,964	31 Oct 1995	Fevig et al.
		5,563,127	08 Oct 1996	Amparo et al.
		5,574,014	12 Nov 1996	Claeson et al.
		5,585,360	17 Dec 1996	de Nanteuil et al.
		5,658,885	19 Aug 1997	Lee et al.
		5,681,978	28 Oct 1997	Matteson et al.
		5,731,439	24 Mar 1998	Carini et al.
		5,780,454	14 Jul 1998	Adams et al.
		5,814,622	29 Sep 1998	de Nanteuil et al.
		6,066,730	23 May 2000	Adams et al.
▼		6,313,096	06 Nov 2001	Claeson et al.

EXAMINER SIGNATURE:	/Yevgeny Valenrod/	DATE CONSIDERED:	01/26/2007
--------------------------------	--------------------	-----------------------------	------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

FEB 24 2004




INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Attorney Docket Number	6613-66750
		Application Number	10/659,178
		Filing Date	September 9, 2003
		First Named Inventor	David Jonathan Madge
		Art Unit	1621
		Examiner Name	To be assigned
	6,465,433	15 Oct 2002	Adams et al.

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Date	Country
YV		0471651	19 Feb 1992	EPC
		WO 92/07869	14 May 1992	WIPO/PCT
		WO 94/21650	29 Sep 1994	WIPO/PCT
		WO 94/25049	10 Nov 1994	WIPO/PCT
		WO 95/09634	13 Apr 1995	WIPO/PCT
		WO 95/09858	13 Apr 1995	WIPO/PCT
		WO 95/09859	13 Apr 1995	WIPO/PCT
		WO 96/13266	09 May 1996	WIPO/PCT
		WO 96/20689	11 Jul 1996	WIPO/PCT
		WO 97/05161	13 Feb 1997	WIPO/PCT
		WO 98/31688	23 Jul 1998	WIPO/PCT
		WO 99/26652	03 Jun 1999	WIPO/PCT
		WO 00/35904	22 Jun 2000	WIPO/PCT
		WO 00/35905	22 Jun 2000	WIPO/PCT
		WO 00/41715	20 Jul 2000	WIPO/PCT
V		WO 01/41796	14 Jun 2001	WIPO/PCT

EXAMINER SIGNATURE:	/Yevgeny Valenrod/	DATE CONSIDERED:	01/26/2007
---------------------	--------------------	------------------	------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.



**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Attorney Docket Number	6613-66750
Application Number	10/659,178
Filing Date	September 9, 2003
First Named Inventor	David Jonathan Madge
Art Unit	1621
Examiner Name	To be assigned

YV		WO 01/02424	11 Jan 2001	WIPO/PCT
YV		WO 02/36157	10 May 2002	PCT
YV		WO 02/059130	01 Aug 2002	WIPO/PCT
YV		WO 02/059131	01 Aug 2002	WIPO/PCT
YV		WO 03/007984	30 Jan 2003	WIPO/PCT

Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS
YV		Claeson et al., <i>Thromb Haemostas</i> , Vol. 65, p. 1289, 1991.
		Claeson et al., "Novel peptide mimetics as highly efficient inhibitors of thrombin based on modified D-Phe-Pro-Arg sequences," in <i>Peptides, Chemistry and Biology</i> , Smith J A, Rivier J E, Eds., Escom: Leiden pp. 824-825, 1992.
		Claeson et al., <i>Biochem J</i> 290:309-312, 1993.
		Claeson et al., <i>The Design of Synthetic Inhibitors of Thrombin</i> 340:83-89, 1993.
		Claeson, <i>Blood Coagulation and Fibrinolysis</i> 5:411-436, 1994.
		Coburn, <i>Exp. Opin. Ther. Patents</i> 11(5):721-738, 2001.
		Contreras et al., <i>J. Org. Chem.</i> 246:213-217, 1983.
		Deadman et al., <i>J. Medicinal Chemistry</i> 38:1511-1522, 1995.
		Deadman et al., <i>J. Enzyme Inhibition</i> 9:29-41, 1995.
		Elgendy et al., <i>Thromb Haemostas</i> 65:775, 1991.
		Elgendy et al., <i>Tetrahedron Letters</i> 33(29):4209-4212, 1992.
		Elgendy et al., <i>The Design of Synthetic Inhibitors of Thrombin</i> 340:173-178, 1993.
▼		Elgendy et al., <i>Tetrahedron</i> 50(12):3803-3812, 1994.

EXAMINER SIGNATURE:	/Yevgeny Valenrod/	DATE CONSIDERED:	01/26/2007
---------------------	--------------------	------------------	------------


* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Attorney Docket Number	6613-66750
		Application Number	10/659,178
		Filing Date	September 9, 2003
		First Named Inventor	David Jonathan Madge
		Art Unit	1621
		Examiner Name	To be assigned
YV		Esmail et al., <i>Thrombosis and Haemostasis</i> 6:1318, 1995.	
		Esmail et al., <i>Thrombosis and Haemostasis</i> 5:91-92, 1997.	
		Esmail et al., <i>Thrombosis and Haemostasis</i> 5:498-499, 1997.	
		Gerrard et al., <i>Thrombosis and Haemostasis</i> 6:1307, 1995.	
		Gustafsson et al., <i>Thrombosis Research</i> 101:171-181, 2001.	
		Katz et al., <i>Biochemistry</i> 34(26):8264-8280, 1995.	
		Martichonok et al., <i>J. Am. Chem. Soc.</i> 118:950-958, 1996.	
		Matt et al., <i>Bioorg. Med. Chem.</i> 8:2291-2303, 2000.	
		Matteson, <i>Chem. Rev.</i> 89:1535-1551, 1989.	
		Matteson et al., <i>J. Org. Chem.</i> 61:6047-6051, 1996.	
		Metternich et al., <i>Naunyn-Schmiedeberg's Arch Pharmacol</i> 97:345, 1992.	
		Philipp et al., <i>The Design of Synthetic Inhibitors of Thrombin</i> 340:67-77, 1993.	
		Rewinkel et al., <i>Current Pharmaceutical Design</i> 5:1043-1075, 1999.	
		Saitoh et al., <i>Pharmaceutical Research</i> 16(11):1786-1789, 1999.	
		Sanderson et al., <i>Current Medicinal Chemistry</i> 5:289-304, 1998.	
		Skordalakes et al., <i>Biochemistry</i> 37(41):14420-14427, 1998.	
		Spencer et al., <i>Tetrahedron</i> 58:1551-1556, 2002.	
		Stahl et al., <i>Handbook of Pharmaceutical Salts Properties, Selection, and Use</i> , Verlag Helvetica Chimica Acta, Postfach, CH-8042 Zürich, Switzerland, 2002.	
V		Tapparelli et al., "The Journal of Biological Chemistry" 268(7):4734-4741, 1993.	

EXAMINER SIGNATURE:	/Yevgeny Valenrod/	DATE CONSIDERED:	01/26/2007
------------------------	--------------------	---------------------	------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	6613-66750
Application Number	10/659,178
Filing Date	September 9, 2003
First Named Inventor	David Jonathan Madge
Art Unit	1621
Examiner Name	To be assigned

EXAMINER SIGNATURE:	/Yevgeny Valenrod/	DATE CONSIDERED:	01/26/2007
------------------------	--------------------	---------------------	------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.